JP2023511963A5 - - Google Patents

Info

Publication number
JP2023511963A5
JP2023511963A5 JP2022545037A JP2022545037A JP2023511963A5 JP 2023511963 A5 JP2023511963 A5 JP 2023511963A5 JP 2022545037 A JP2022545037 A JP 2022545037A JP 2022545037 A JP2022545037 A JP 2022545037A JP 2023511963 A5 JP2023511963 A5 JP 2023511963A5
Authority
JP
Japan
Application number
JP2022545037A
Other languages
Japanese (ja)
Other versions
JP2023511963A (ja
JPWO2021149015A5 (https=
Filing date
Publication date
Priority claimed from KR1020200009565A external-priority patent/KR20210095781A/ko
Application filed filed Critical
Publication of JP2023511963A publication Critical patent/JP2023511963A/ja
Publication of JP2023511963A5 publication Critical patent/JP2023511963A5/ja
Publication of JPWO2021149015A5 publication Critical patent/JPWO2021149015A5/ja
Pending legal-status Critical Current

Links

JP2022545037A 2020-01-24 2021-01-23 多重特異性抗体、それを含む組成物、およびベクター、ならびにそれらの使用 Pending JP2023511963A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2020-0009565 2020-01-24
KR1020200009565A KR20210095781A (ko) 2020-01-24 2020-01-24 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US16/878,255 2020-05-19
US16/878,255 US20210230285A1 (en) 2020-01-24 2020-05-19 Multispecific antibodies, compositions comprising the same, and vectors and uses thereof
PCT/IB2021/050519 WO2021149015A1 (en) 2020-01-24 2021-01-23 Multispecific antibodies, compositions comprising the same, and vectors and uses thereof

Publications (3)

Publication Number Publication Date
JP2023511963A JP2023511963A (ja) 2023-03-23
JP2023511963A5 true JP2023511963A5 (https=) 2024-01-25
JPWO2021149015A5 JPWO2021149015A5 (https=) 2024-01-25

Family

ID=76969825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022545037A Pending JP2023511963A (ja) 2020-01-24 2021-01-23 多重特異性抗体、それを含む組成物、およびベクター、ならびにそれらの使用

Country Status (17)

Country Link
US (3) US20210230285A1 (https=)
EP (1) EP4093764A4 (https=)
JP (1) JP2023511963A (https=)
KR (2) KR20210095781A (https=)
CN (1) CN116113642A (https=)
AU (1) AU2021211241A1 (https=)
CA (1) CA3165029A1 (https=)
CL (2) CL2022001993A1 (https=)
CO (1) CO2022011885A2 (https=)
CR (1) CR20220415A (https=)
DO (1) DOP2022000150A (https=)
EC (1) ECSP22065625A (https=)
IL (1) IL294917A (https=)
JO (1) JOP20220171A1 (https=)
MX (1) MX2022009150A (https=)
PH (1) PH12022551828A1 (https=)
WO (1) WO2021149015A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
KR20210095781A (ko) * 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2023057369A2 (en) * 2021-10-04 2023-04-13 Astrazeneca Ab Treatment of lupus
CN114149508B (zh) * 2021-11-25 2023-04-28 苏州普乐康医药科技有限公司 一种结合cd40l的融合蛋白及其应用
JP2025528881A (ja) * 2022-08-19 2025-09-02 プロアブテック カンパニー リミテッド 単鎖可変断片の改変タンパク質
CN121532422A (zh) 2023-11-28 2026-02-13 H.隆德贝克有限公司 用于在治疗甲状腺眼病中使用的融合蛋白

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
KR20000070034A (ko) 1997-01-10 2000-11-25 아스트루 마이클 제이 항 cd40l 화합물로 신염성 루푸스를 치료하는 방법
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
CN1202864C (zh) 1997-05-17 2005-05-25 拜奥根有限公司 Cd40:cd154结合阻断物在制备预防逆适应性免疫应答,特别是移植物排斥反应的药物中的用途
WO1998058672A1 (en) 1997-06-20 1998-12-30 Biogen, Inc. Cd154 blockade therapy for therapeutic protein inhibitor syndrome
BR9810620A (pt) 1997-06-20 2000-10-03 Biogen Inc Terapia de bloqueio de cd154 para transplante de tecido da ilhota pancreática
NZ518483A (en) 1999-10-22 2004-03-26 Biogen Inc Use of CD40:CD154 binding interruptor to treat immunological complications of the eye
US8101553B1 (en) 2000-02-22 2012-01-24 Medical & Biological Laboratories Co., Ltd. Antibody library
GB0019820D0 (en) 2000-08-12 2000-09-27 Koninkl Philips Electronics Nv Selective delivery of data
FI112501B (fi) 2001-05-18 2003-12-15 Valtion Teknillinen Heveiiniä sitovat monoklonaaliset vasta-aineet
ES2316574T3 (es) 2001-06-12 2009-04-16 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Anticuerpo de tipo humano contra el factor viii de la coagulacion sanguinea.
EP1439192A1 (en) 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Neuropilin-1 inhibitors
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
KR20060090651A (ko) 2003-07-03 2006-08-14 유니크롭 엘티디 신규한 루비스코 프로모터 및 이의 용도
CN101031588A (zh) 2004-06-01 2007-09-05 多曼蒂斯有限公司 药物组合物,融合物和结合物
EA012622B1 (ru) 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
EA014226B1 (ru) 2004-07-26 2010-10-29 Байоджен Айдек Ма Инк. Антитела к cd154, их фрагменты и способы применения антител и фрагментов
BRPI0514259A (pt) 2004-08-11 2008-06-03 Trubion Pharmaceuticals Inc proteìna de fusão de domìnio de ligação
JP2008515889A (ja) 2004-10-05 2008-05-15 ジェネンテック・インコーポレーテッド 毒性の低下した治療剤
EP2024396A2 (en) 2004-12-02 2009-02-18 Domantis Limited Plad domain peptides with increased serum half life due to conjugation to domain antibodies
US8709219B2 (en) 2005-03-10 2014-04-29 Panasonic Corporation Structured diamond tool made by focused ion beam nanomachining
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
JP4940013B2 (ja) 2006-07-31 2012-05-30 富士通株式会社 半導体装置に対する同時動作信号ノイズ見積り方法、およびプログラム
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
KR20120017469A (ko) 2007-01-05 2012-02-28 유니버시티 오브 취리히 질환 특이적 결합 분자 및 표적을 제공하는 방법
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
PT2125894T (pt) 2007-03-22 2019-02-27 Biogen Ma Inc Proteínas de ligação incluindo anticorpos, derivados de anticorpos e fragmentos de anticorpos que se ligam especificamente ao cd154 e as suas utilizações
WO2008127655A1 (en) 2007-04-13 2008-10-23 Biogen Idec Ma Inc. Anti-alpha 6 beta 4 integrin antibodies and uses therof
AU2008261042A1 (en) 2007-06-08 2008-12-11 Dow Global Technologies Inc. Expression of soluble antibody fragment by truncation of CH1 domain
WO2009002380A2 (en) 2007-06-26 2008-12-31 The Trustees Of The University Of Pennsylvania Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20110033476A1 (en) 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2009120922A2 (en) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
CA2730073A1 (en) 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
WO2010014854A2 (en) 2008-07-31 2010-02-04 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
CA2737667A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Targeted binding agents directed to cd105 and uses thereof
HRP20170374T1 (hr) 2008-09-26 2017-05-05 Ucb Biopharma Sprl Biološki proizvodi
KR101740066B1 (ko) 2008-12-05 2017-05-25 글락소 그룹 리미티드 프로테아제 저항성 폴리펩티드를 선택하는 방법
JP2012527473A (ja) 2009-05-20 2012-11-08 セラクローン サイエンシーズ, インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
JP6086528B2 (ja) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有する成長ホルモン
US8974788B2 (en) 2009-08-14 2015-03-10 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
MX358013B (es) 2009-11-13 2018-08-01 Amgen Inc Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
SI2501817T2 (sl) 2010-02-08 2021-09-30 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
EP3165540A1 (en) 2010-04-13 2017-05-10 Celldex Therapeutics, Inc. Antibodies that bind human cd27 and uses thereof
US20120213771A1 (en) 2010-04-13 2012-08-23 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
AU2011286407A1 (en) 2010-08-06 2013-02-21 Amgen Use of HER3 binding agents in prostate treatment
AU2012205663B2 (en) 2011-01-10 2017-02-02 Emory University Antibodies directed against influenza
JP2014506580A (ja) 2011-02-14 2014-03-17 セラクローン サイエンシーズ, インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
SG193402A1 (en) 2011-03-15 2013-10-30 Theraclone Sciences Inc Compositions and methods for the therapy and diagnosis of influenza
BR112013026828A2 (pt) 2011-04-21 2016-11-29 Bristol Myers Squibb Co polipeptídeos de anticorpo que antagonizam cd40
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
BR112013031485B1 (pt) 2011-06-10 2022-06-14 Medimmune, Llc Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais
RS59728B1 (sr) 2011-08-05 2020-02-28 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
SMT202000091T1 (it) * 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
JP5413432B2 (ja) 2011-10-20 2014-02-12 コニカミノルタ株式会社 画像形成装置
BR112014011028B1 (pt) 2011-11-07 2021-03-02 Medimmune, Llc anticorpo biespecífico, composição, e, uso da composição
ES2842201T3 (es) 2012-02-23 2021-07-13 Daiichi Sankyo Europe Gmbh Inhibidor de HER3 para modulación de radiosensibilidad
IN2014DN08163A (https=) 2012-03-06 2015-05-01 Regeneron Pharma
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
JP2015520172A (ja) 2012-05-31 2015-07-16 ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. Dll−4に結合する抗原結合蛋白質
HK1204557A1 (en) 2012-05-31 2015-11-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-l1
RU2014153674A (ru) 2012-06-05 2016-07-27 Регенерон Фармасьютикалз, Инк. Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи
JO3462B1 (ar) 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JP2015535005A (ja) 2012-11-06 2015-12-07 メディミューン,エルエルシー 抗シュードモナス属(Pseudomonas)PslおよびPcrV結合分子を用いた併用治療
CN105189545A (zh) 2013-03-13 2015-12-23 瑞泽恩制药公司 常见轻链小鼠
WO2014160202A1 (en) 2013-03-13 2014-10-02 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20160032014A1 (en) 2013-03-15 2016-02-04 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
JP2016519688A (ja) 2013-04-22 2016-07-07 セラクローン サイエンシーズ, インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
JP6267792B2 (ja) 2013-06-28 2018-01-24 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素a之抗體及其用途
MX371328B (es) * 2013-08-30 2020-01-27 Aprilbio Co Ltd Constructo de fusion de la fraccion efectora del fragmento de union a antigeno (fab) de anti-albumina de suero y su metodo de preparacion.
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
KR102399277B1 (ko) 2014-04-10 2022-05-18 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
SG10201913084PA (en) 2014-09-23 2020-03-30 Regeneron Pharma Anti-il-25 antibodies and uses thereof
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
MA41459A (fr) * 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
WO2016135239A1 (en) * 2015-02-25 2016-09-01 Biotecnol Limited Fusion protein comprising three binding domains to her2
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
US11597778B2 (en) 2015-04-07 2023-03-07 The Trustees Of The University Of Pennsylvania Human monoclonal autoantibodies to ADAMTS13 and uses thereof
EA201792573A1 (ru) * 2015-05-21 2018-04-30 Харпун Терапьютикс, Инк. Триспецифические связанные белки и способы их применения
TW201702272A (zh) 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Prame肽專一性類t細胞受體抗體
US11359010B2 (en) 2015-07-13 2022-06-14 UNIVERSITé LAVAL Humanized anti-S100A9 antibody and uses thereof
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗angptl8抗體及其用途
LT3353212T (lt) 2015-09-23 2021-12-27 Regeneron Pharmaceuticals, Inc. Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗lag3抗體及其用途
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
CN109476756B (zh) * 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448875A4 (en) 2016-04-29 2020-04-08 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
IL323024A (en) 2016-05-20 2025-10-01 Regeneron Pharma Methods for breaking immunological tolerance using multiple guide RNAs
US10738126B2 (en) 2016-06-10 2020-08-11 Regeneron Pharmaceuticals, Inc. Anti-GITR antibodies and uses thereof
SI3468586T1 (sl) 2016-06-14 2025-01-31 Xencor, Inc. Bispecifična protitelesa za zaviralce kontrolnih točk
ES2984352T3 (es) 2016-06-14 2024-10-29 Regeneron Pharma Anticuerpos anti-C5 y usos de los mismos
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018009732A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
EP3489262A4 (en) 2016-07-19 2020-07-08 Ibentrus, Inc. BISPECIFIC PROTEINS AND PROCESSES FOR THEIR PREPARATION
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MX2019003325A (es) 2016-09-23 2019-08-05 Regeneron Pharma Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos.
MY194596A (en) 2016-09-23 2022-12-06 Regeneron Pharma Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates
US11667697B2 (en) 2016-10-19 2023-06-06 Vanderbilt University Human orthopoxvirus antibodies and methods of use therefor
US10550192B2 (en) 2016-11-08 2020-02-04 Regeneron Pharmaceuticals, Inc. Antigen-binding proteins that antagonize leptin receptor
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
WO2018094112A1 (en) 2016-11-17 2018-05-24 Regeneron Pharmaceuticals, Inc. Methods of treating obesity with anti-angptl8 antibodies
EP3548515B1 (en) 2016-12-01 2026-01-21 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
WO2018115859A1 (en) 2016-12-20 2018-06-28 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素a毒素之人類抗體
CA3053348A1 (en) 2017-02-10 2018-08-16 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
CN110662768B (zh) 2017-05-24 2024-01-30 Als治疗发展学会 治疗性抗cd40配体抗体
KR20200018781A (ko) * 2017-06-19 2020-02-20 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 반감기 연장 폴리펩티드를 갖는 융합 단백질
WO2019201866A1 (en) 2018-04-16 2019-10-24 Swedish Orphan Biovitrum Ab (Publ) Fusion protein
WO2021006604A1 (ko) 2019-07-08 2021-01-14 주식회사 프로젠 신규 융합단백질 및 그의 용도
KR20210095781A (ko) * 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Similar Documents

Publication Publication Date Title
JP2023511963A5 (https=)
CN305526991S (https=)
CN306342441S (https=)
CN305580314S (https=)
CN305580329S (https=)
CN305668770S (https=)
CN305670904S (https=)
CN305707421S (https=)
CN305723566S (https=)
CN305724072S (https=)
CN305724701S (https=)
CN305749303S (https=)
CN305793313S (https=)
CN305794455S (https=)
CN305797222S (https=)
CN305798241S (https=)
CN305798593S (https=)
CN305799080S (https=)
CN305804390S (https=)
CN305829074S (https=)
CN305829769S (https=)
CN306142821S (https=)
CN306183333S (https=)
CN306193571S (https=)
CN306194597S (https=)